Introduction: The long-term effects of an intensified induction regimen are unknown. In this pilot, randomized, prospective study we evaluate the effect of a short-term four-drugs induction regimen in patients with high baseline viral load. Methods: Naive patients with HIV-RNA100.000 copies/ml receiving TDF'FTC'EFV'RAL (group ER) for 4 months and were then simplified to TDF'FTC'EFV. Two randomized control groups treated ab-initio with TDF'FTC'EFV (E) or TDF'FTC'RAL (R) were used. Results: 19 patients with a mean age of 38 years and mean baseline CD4 count of 334 (SD 216) cells/mcL and HIV-RNA of 5.47 log (SD 0.32) copies/mL were enrolled. No baseline significant difference was observed among groups. Early HIV-RNA reduction was significantly higher in ER compared to the other groups from week 1 to week 4 (P from 0.026 to 0.003) (figure 1), thereafter HIV-RNA values were comparable among the groups. At week 96, all patients had an HIV-RNA B 50 copies/mL, however only patients in the ER group had in all cases an HIV-RNA level B 3 copies/mL with a statistically significant difference compared to E (60%; P00.038) and R (50%; P00.020). At 96 weeks, CD4 cell median counts were 765 cells/mcL for ER, 600 cells/mcL for E and 771 for R (P 00.16), however patients in the ER group presented a lower proportion of activated CD4'CD38'HLADR' cells (1.9% versus 3.9 and 3.8%) and CD8'CD38'HLADR' cells (10.3% versus 16.8 and 16.5%) and a significantly better CD4/CD8 ratio (0.98 versus 0.53 and 0.61; P00.03). Conclusions: A four-drug regimen in naive patients with high pre-therapy viral load improves early virologic response. A quick drop of HIV-RNA seems to correlate with a sustained virologic response. Although limited in time (four months), the four-drug regimens correlates with an improved immunological response as measured by the CD4/CD8 ratio or the percentage of activated CD4' and CD8' cells. The reasons why this happens deserve further studies. This study highlights the importance of a personalised therapy especially in high risk patients. 
